(Q41107871)

26 September 2017

1 reference

title

Inhibitors in congenital haemophilia (English)

1 reference

26 September 2017

0 references

Brettler DB

1

1 reference

26 September 2017

publication date

1 June 1996

1 reference

Best Practice and Research: Clinical Haematology

26 September 2017

published in

1 reference

26 September 2017

volume

9

1 reference

26 September 2017

issue

2

1 reference

26 September 2017

page(s)

319-329

1 reference

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Acute myocardial infarction in a young hemophiliac patient during therapy with Factor IX concentrate and epsilon aminocaproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Synthetic sorbents for removal of factor VIII inhibitors from haemophilic A plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Continuous infusion of monoclonal antibody-purified factor VIII: rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Factor VIII inhibitors. Etiology, characterization, natural history, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

The molecular genetic analysis of haemophilia A; characterization of six partial deletions in the factor VIII gene

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2896%2980066-7

7 January 2021

10.1016/S0950-3536(96)80066-7

Identifiers

DOI

1 reference

26 September 2017

1 reference